SAN
DIEGO, Sept. 1, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, is scheduled to present and host investor
meetings at the 2022 Wells Fargo Healthcare Conference being held
in Boston, MA on September 7-9, 2022.
Details for the presentation are as follows:
Event:
|
2022 Wells Fargo
Healthcare Conference
|
Format:
|
Presentation and 1x1
Meetings
|
Presentation
Date:
|
Thursday, September 8,
2022
|
Presentation
Time:
|
5:35 a.m. PT / 8:35
a.m. ET
|
A live audio webcast of the presentation will be available in
the Investor Relations section of the Company's website.
Replays of the audio webcast will be available for 90 days
following the conference.
About Halozyme Therapeutics,
Inc.
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20,
Halozyme's commercially-validated solution is used to facilitate
the delivery of injected drugs and fluids in order to reduce the
treatment burden to patients. Having touched more than 600,000
patient lives in post-marketing use in five commercialized products
across more than 100 global markets, Halozyme has licensed its
ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, AbbVie,
Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO™ and
NOCDURNA® and partnered commercial products and ongoing
product development programs with industry leading pharmaceutical
companies including Teva Pharmaceutical, Covis Pharma, Pfizer and
Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-2022-wells-fargo-healthcare-conference-301616387.html
SOURCE Halozyme Therapeutics, Inc.